"The aim of the PredictAD project is to develop an objective indicator to diagnose Alzheimer's disease at the earliest stage possible. Current diagnostic guidelines emphasise the importance of various biomarkers in diagnostics.
We have developed novel approaches to extract biomarkers from imaging data, electrophysiological data and blood samples, and a unique and clinically useful software tool for integrating all these heterogeneous measurements." says the Scientific Coordinator of the project, Dr Jyrki Lötjönen from VTT Technical Research Centre of Finland.
Magnetic resonance imaging for identifying atrophy
Atrophy in the mediotemporal lobe is a well-known hallmark of Alzheimer's disease. Magnetic resonance imaging is an excellent tool for measuring this tissue loss. In current clinical practice, images are interpreted mostly only by visual inspection but there is a great need for objective measurements.
PredictAD has developed several methods to meet this need. "We have managed to develop efficient tools for measuring the size of the hippocampus, the atrophy rate of the hippocampus, and two modern approaches based on comparing patient data with previously diagnosed cases available in large databases." says the leader of the imaging biomarkers work-package, professor Daniel Rueckert from Imperial College London. Positron emission tomography (PET) imaging is another imaging technology studied in the project. A novel tracer developed recently especially for diagnostics of Alzheimer's disease provides promises for very early diagnosis of the disease.
Detecting changes in the electrophysiology of the brain
Alzheimer's disease is known to affect the electromagnetic activity of the brain. In PredictAD, we have studied the performance of a novel technology, transcranial magnetic stimulation (TMS) combined with electroencephalographic (EEG) measures in detecting the disease. The strength of TMS/EEG is that it allows direct and non-invasive perturbation of the human cerebral cortex without requiring the subject's collaboration. Our study has shown significant changes in Alzheimer's patients compared with healthy aging people.
Non-invasive techniques to find biomarkers of the disease
Molecular level biomarkers are currently under extensive studies in Alzheimer's research. Many biomarkers, such as tau proteins and b-amyloid 42, measured from the cerebrospinal fluid (CSF), the liquid surrounding the cerebral cortex, have been found to be strongly related with the disease. One major challenge of these biomarkers is that taking samples from CSF is an invasive measurement limiting their usability in early diagnostics. Blood samples would be an excellent source for detecting Alzheimer's disease as blood sampling is not considered an invasive technique. PredictAD has studied the role of metabolomic and protein compounds in Alzheimer's disease from blood samples. The preliminary results reveal several promising compounds.
Methodology for measuring the state of the patient
Currently, clinicians make the final diagnosis by combining heterogeneous measurements with information from interviews of the patient and relatives. This process involves subjective reasoning and requires strong expertise from the clinicians. Modern hospitals have huge data reserves containing hidden information that could be utilised in diagnostics by systematic mathematical modelling.
PredictAD has designed a totally novel approach for measuring objectively the state of the patient. This decision support system, developed in close collaboration with clinicians, compares patient measurements with measurements of other patients in large databases and provides at the end an index and graphical representation reflecting the state of the patient. "The PredictAD tool provides a new option to support decision making", says Prof. Hilkka Soininen from the University of Eastern Finland, leading the clinical validation of the project.
Possibilities for significant savings in health costs
Prof. Gunhild Waldemar from Copenhagen University Hospital, Rigshospitalet emphasises the importance of the Alzheimer's disease research: "Successful, early diagnostics combined with the novel drugs under development and early psychosocial care may delay the institutionalisation of patients, reducing suffering and the costs to the society. It has been calculated that delaying the onset of the disease by five years would halve all costs of Alzheimer's disease and delaying onset and progression by only one year would reduce the number of Alzheimer's cases by about 10%."
"Diagnostic companies like GE Healthcare and pharmaceutical companies are investing heavily in this area. Commercialisation of the results is already ongoing in PredictAD", says Dr Lennart Thurfjell from GE Healthcare Ltd leading the activities of dissemination and exploitation.
Dementia has been recently identified as a health priority both in Europe and in the USA. Alzheimer's disease, the most common cause of dementia, alone accounts for costs equivalent to about 1% of the gross domestic product (GDP) of the whole world and the number of persons affected will double in the next 20 years. Early diagnostics plays a key role in solving the problem because treatments of this irreversible disease should be started in an early phase to be efficient. Various treatments are currently under extensive development. So far, the lack of systematic and objective ways to identify persons for treatments has been apparent.
With a consortium of top-level European research and industry partners, the PredictAD project takes an important step towards an early approach to Alzheimer's disease prediction and management. Public and private partners from eight research, academic, industrial and medical organisations from five different European countries form the consortium: VTT (Finland), GE Healthcare (UK), Nextim Ltd. (Finland), University of Eastern Finland (Finland), Imperial College London (UK), Karolinska Institutet (Sweden), University of Milan (Italy) and Copenhagen University Hospital, Rigshospitalet (Denmark).
PredictAD is organising a workshop in Kuopio, Finland, on June 15, 2011. The purpose of the workshop is to present and discuss results of the PredictAD project and recent innovations for the early diagnosis of Alzheimer's disease.
Jyrki Lötjönen | EurekAlert!
The genes are not to blame
20.07.2018 | Technische Universität München
Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz
A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.
The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
20.07.2018 | Power and Electrical Engineering
20.07.2018 | Information Technology
20.07.2018 | Materials Sciences